Inclusion Criteria:

1. Subject must be ≥ 18 years of age.

2. Subjects must have histological or cytological confirmation of locally advanced or
metastatic solid tumor, and a documented Breast Cancer Gene 1 or 2 mutation, or
high grade serous ovarian, fallopian tube, or primary peritoneal cancer.

3. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2

4. Subjects must have adequate hematologic, renal, and hepatic function as follows:
a. Bone Marrow: Absolute neutrophil count (ANC ≥ 1,500/mm3 (1.5 ≥ 109/L); Platelets
≥ 100,000/mm3 (100 ≥ 109/L); Hemoglobin ≥ 9.0 g/dL (1.4 mmol/L) (hemoglobin
unsupported by transfusion b. Subject has adequate renal function as demonstrated
by serum creatinine value of ≤ 1.5 x the upper limit of normal (ULN) and either an
estimated creatinine clearance value of ≥ 50 mL/min as determined by the
Cockcroft-Gault formula or a creatinine clearance value of ≥ 50 mL/min/1.73 m2 based
on a 24-hour urine collections c. Subject has adequate liver function as
demonstrated by serum bilirubin ≤ 1.5 x ULN and Aspartate Aminotransferase (AST) and
Alanine Transaminase (ALT) ≤ 2.5 ULN. For subjects with liver metastasis, AST and
ALT < 5 x ULN. Partial Thromboplastin Time (PTT) must be ≤ ULN and INR < 1.5. -
Subjects on anticoagulant (such as Coumadin) are allowed on study and will have PTT
and International Normalize Ratio (INR) as determined by the Investigator.

5. Women of childbearing potential must agree to use adequate contraception prior to
study entry, for the duration of the study participation, and for 90 days following
completion of therapy. Women of childbearing potential must have a negative serum
pregnancy test within 21 days prior to initiation of treatment and a negative urine
pregnancy test on the first day of study drug administration. Post-menopausal women
must be amenorrheic for at least 12 months to be considered of non-childbearing
potential.

Exclusion Criteria:

1. Expanded cohort only: Subject has previously received a poly (ADP-ribose) polymerase
(PARP) inhibitor.

2. -Subject has received anti-cancer therapy including chemotherapy, immunotherapy,
radiotherapy, biologic or any investigational therapy within a period of 28 days or 5
half lives (whichever is shorter) prior to Study Day 1.

3. Subject has known Central Nervous System (CNS) metastases.

4. Subject has unresolved toxicities from prior anti-cancer therapy, defined as any
Common Terminology Criteria for Adverse Events (CTCAE v 4.0) grade 2 or higher
clinically significant toxicity (excluding alopecia).

5. Subject has had major surgery within 28 days prior to Study Day 1.

6. Clinically significant uncontrolled condition(s) or any medical condition which in
the opinion of the study investigator places the subject at an unacceptably high risk
for toxicities.

7. Psychiatric illness/social situation that would limit compliance with study
requirements.

8. Lactating or pregnant female.